Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: Glutamine vs placebo Quality of life · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment All‐cause mortality at 100 days post‐transplant ( · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.7 [0.5, 0.99] | 4 studies · 612 participants | Low |
Summary of findings: Glutamine vs placebo Frequency of adverse events ( · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 2.68 [0.12, 61.58] | 1 study · 34 participants | Very low |
Summary of findings: Fresh frozen plasma vs no treatment Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.66 [0.2, 2.17] | 2 studies · 383 participants | Very low |
Summary of findings: Fresh frozen plasma vs no treatment Overall survival · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Mortality attributable to hepatic veno‐occlusive disease · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Quality of life · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Frequency of adverse events · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Antithrombin III plus heparin vs heparin alone Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.13 [0.01, 2.15] | 1 study · 30 participants | Very low |
Summary of findings: Antithrombin III plus heparin vs heparin alone Overall survival · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Antithrombin III plus heparin vs heparin alone All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.27 [0.09, 0.87] | 4 studies · 612 participants | Very low |
Summary of findings: Antithrombin III plus heparin vs heparin alone Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Summary of findings: Antithrombin III plus heparin vs heparin alone Quality of life · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Antithrombin III plus heparin vs heparin alone Frequency of adverse events ( · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.29 [0.04, 2.27] | 1 study · 30 participants | Very low |
Summary of findings: Heparin vs low molecular weight heparin Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 1.96 [0.8, 4.77] | 1 study · 93 participants | Very low |
Summary of findings: Heparin vs low molecular weight heparin Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs low molecular weight heparin All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs low molecular weight heparin Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 2.94 [0.12, 70.3] | 1 study · 93 participants | Very low |
Summary of findings: Heparin vs low molecular weight heparin Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs low molecular weight heparin Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.84 [0.3, 2.31] | 1 study · 93 participants | Very low |
Summary of findings: Heparin vs prostaglandin E1 Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 1.2 [0.58, 2.5] | 1 study · 94 participants | Very low |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment Quality of life · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.5 [0.05, 5.33] | 1 study · 94 participants | Very low |
Summary of findings: Heparin vs prostaglandin E1 Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.43 [0.18, 1.02] | 1 study · 94 participants | Very low |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.61 [0.24, 1.55] | 1 study · 93 participants | Very low |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Overall survival · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.2 [0.01, 4.14] | 1 study · 93 participants | Very low |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Quality of life · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment Frequency of adverse events ( · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.9 [0.37, 2.22] | 4 studies · 612 participants | Very low |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Frequency of adverse events ( · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.51 [0.23, 1.15] | 1 study · 93 participants | Very low |
Summary of findings: Heparin vs no treatment Incidence of hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.47 [0.18, 1.26] | 2 studies · 259 participants | Very low |
Summary of findings: Heparin vs no treatment Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | HR 0.65 | 1 study · 161 participants | Very low |
Summary of findings: Heparin vs no treatment All‐cause mortality at 100 days post‐transplant ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | RR 0.66 [0.25, 1.76] | 1 study · 161 participants | Low |
Intervention NR Relapses/death (instead of disease‐free survival）[2] · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | HR 0.95 [0.86, 1.06] | 6 studies · 1426 participants | Low |
Intervention NR Mortality (instead of overall survival)[2] · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | HR 1.05 [0.95, 1.16] | 5 studies · 1355 participants | Moderate |
Intervention NR Death/progress (instead of event‐free survival)[2] · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | HR 1.02 [0.79, 1.32] | 1 study · 161 participants | Low |
Intervention NR Treatment‐related mortality · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Adverse events: hypersensitivity · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | RR 17.13 [0.99, 295.26] | 1 study · 528 participants | Very low |
Intervention NR Adverse events: fatigue · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | RR 7.05 [2.13, 23.36] | 1 study · 528 participants | Very low |
Intervention NR Adverse events: rigor/chills · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | RR 33.25 [2.01, 551.36] | 1 study · 528 participants | Very low |
Intervention NR Adverse events: arthralgia/myalgia · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | RR 19.14 [1.12, 327.24] | 1 study · 528 participants | Very low |
Intervention NR Quality of life · People with AML in first complete remission Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete… (2015) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Ruxolitinib vs placebo Overall survival (number of deaths at · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane | HR 0.51 [0.27, 0.98] | 1 study · 309 participants | Low |
Ruxolitinib vs best available therapy Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis (2015) · Cochrane | RR 1.2 [0.44, 3.28] | 1 study · 219 participants | Low |